ArticleAngewandte Chemie (International ed. in English)2021
Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
Open access · hybridAbstract read
In one paragraph
Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 147 citations in OpenAlex.
- Decoding Enzyme-Inhibitor Kinetic Mechanisms by Isothermal Titration Calorimetry: The Case of SARS-CoV-2 3CLAnalytical chemistry · 2026Article
- Fat or flat? The impact of dipole moment vectors on non-covalent interactions between aromatic tags and macromolecules.Inorganic chemistry frontiers · 2026Article
- Sequential Optimization Approach Toward an Azapeptide-Based SARS-CoV-2 Main Protease Inhibitor.Archiv der Pharmazie · 2025Article
- Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- A Novel Fluorescence Polarization Binding Assay for the Main Protease (MACS pharmacology & translational science · 2025Article
- Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity.Journal of medicinal chemistry · 2025Article
- Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV‑2 Papain-like Protease (PLACS omega · 2025Article
- Identification of SARS-CoV-2 Main Protease Cleavage Sites in Bovine β-Casein.International journal of molecular sciences · 2025Article
- Salamandamide Lipodipeptides Are Biosynthetic Intermediate Shunt Products of the Nonamodular Nonribosomal Peptide Assembly Lines of the Viscosin Family.Journal of natural products · 2025Article
- An isothermal calorimetry assay for determining steady state kinetic and Ensitrelvir inhibition parameters for SARS-CoV-2 3CL-protease.Scientific reports · 2024Article
- Miniaturized Modular Click Chemistry-enabled Rapid Discovery of Unique SARS-CoV-2 MAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease.ACS pharmacology & translational science · 2024Article
- Synthesis, structures and Hirshfeld surface analyses of 2-hy-droxy-Acta crystallographica. Section E, Crystallographic communications · 2024Article
- Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.Antiviral research · 2024Article
- Development of an active-site titrant for SARS-CoV-2 main protease as an indispensable tool for evaluating enzyme kinetics.Acta pharmaceutica Sinica. B · 2024Article
- Preclinical evaluation of the SARS-CoV-2 MNature microbiology · 2024Article
- Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity.ACS pharmacology & translational science · 2024Article
- On the origins of SARS-CoV-2 main protease inhibitors.RSC medicinal chemistry · 2024Review
- Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.European journal of medicinal chemistry · 2023Review
- Prediction and design of protease enzyme specificity using a structure-aware graph convolutional network.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Julian BreidenbachPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0002-5986-348X
Carina LemkePharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0003-4638-3396
Thanigaimalai PillaiyarPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0001-5575-8896
Laura SchäkelPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0002-8743-8261
Ghazl Al HamwiPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0002-6325-381X
Miriam DiettPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.
Robin GedscholdPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.
Nina GeigerInstitute for Virology and Immunobiology, Julius-Maximilians-University Würzburg, Versbacher Strasse 7, 97078, Würzburg, Germany.ORCID 0000-0002-2974-6290
Vittoria LopezPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0002-6364-7755
Salahuddin MirzaPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0002-4944-8282
Vigneshwaran NamasivayamPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0003-3031-3377
Anke C SchiedelPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0002-8114-3139
Katharina SylvesterPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.
Dominik ThimmPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0002-4437-232X
Christin VielmuthPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.
Lan Phuong VuPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.
Maria ZyulinaPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.
Jochen BodemInstitute for Virology and Immunobiology, Julius-Maximilians-University Würzburg, Versbacher Strasse 7, 97078, Würzburg, Germany.ORCID 0000-0003-1908-4091
Michael GütschowPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0002-9376-7897
Christa E MüllerPharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany), E-mails.ORCID 0000-0002-0013-6624
University of Bonn · DEUniversity of Würzburg · DE
Funding
Bundesministerium für Bildung und Forschung BIGS DrugS - 16GW0025
Abstract
The main protease of SARS-CoV-2 (M
Indexed as
COVID-19 Drug TreatmentAntiviral AgentsCoronavirus 3C ProteasesCOVID-19Drug DesignDrug DiscoveryHEK293 CellsHigh-Throughput Screening AssaysHumansMolecular Docking SimulationNitrilesProtease InhibitorsPyridinesSARS-CoV-2Virus Internalization3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesNitrilesProtease InhibitorsPyridinesazapeptide nitrilesfluorogenic substrateshigh throughput screeningpyridinyl 1H-indole-carboxylatesSARS-CoV-2 main protease
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.